Overall, CDK4/6i, in addition to their direct cytostatic tumour action, would greatly facilitate response of MPMs to immune checkpoint inhibitors including the newly FDA‐approved combination of nivolumab and ipilimumab [2, 11, 132]. This evidence concerns the gene CDK4 and neoplasm.